泛素特异性蛋白酶对肿瘤放疗敏感性的影响

doi:10.3760/cma.j.issn.1673-422X.2019.07.006

摘要/Abstract

摘要： 泛素特异性蛋白酶是去泛素化酶家族中的一员，能逆转蛋白质的泛素化降解，从而达到稳定蛋白质的目的。其通过调控肿瘤细胞的DNA损伤、细胞周期、核转录因子κB信号通路、Nrf2Keap1信号通路、癌基因cmyc等，影响肿瘤对放疗的敏感性，有望成为肿瘤放疗增敏的新靶点。

关键词: 肿瘤, 辐射耐受性, 泛素特异性蛋白酶

Abstract: Ubiquitin-specific protease is a member of the deubiquitinating enzyme family, which can reverse the ubiquitination of proteins and stabilize proteins. It affects radiosensitivity of tumor by regulating DNA damage, cell cycle, nuclear factor-κB signaling pathway, Nrf2-Keap1 signaling pathway and oncogene c-myc. It is expected to become a new target for tumor radiotherapy sensitization.

Key words: Neoplasms, Radiation tolerance, Ubiquitin specific proteases

周奇芬，吴春林. 泛素特异性蛋白酶对肿瘤放疗敏感性的影响[J]. 国际肿瘤学杂志, 2019, 46(7): 420-422.

Zhou Qifen, Wu Chunlin. Effect of ubiquitin-specific protease on radiosensitivity of tumor[J]. Journal of International Oncology, 2019, 46(7): 420-422.

参考文献

［1］ Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2018, 68(6): 394424. DOI: 10.3322/caac.21492. ［2］ Bristow RG, Alexander B, Baumann M, et al. Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology［J］. Lancet Oncol, 2018, 19(5): e240e251. DOI: 10.1016/S14702045(18)300962. ［3］ de Poot SAH, Tian G, Finley D. Meddling with fate: the proteasomal deubiquitinating enzymes［J］. J Mol Biol, 2017, 429(22): 35253545. DOI: 10.1016/j.jmb.2017.09.015. ［4］ Wieringa HW, van der Zee AG, de Vries EG, et al. Breaking the DNA damage response to improve cervical cancer treatment［J］. Cancer Treat Rev, 2016, 42: 3040. DOI: 10.1016/j.ctrv.2015.11.008. ［5］ Wang Z, Zhang H, Liu J, et al. USP51 deubiquitylates H2AK13, 15ub and regulates DNA damage response［J］. Genes Dev, 2016, 30(8): 946959. DOI: 10.1101/gad.271841.115. ［6］ Zhang L, Nemzow L, Chen H, et al. The deubiquitinating enzyme USP24 is a regulator of the UV damage response［J］. Cell Rep, 2015, 10(2): 140147. DOI: 10.1016/j.celrep.2014.12.024. ［7］ Zhang W, Sartori MA, Makhnevych T, et al. Generation and validation of intracellular ubiquitin variant inhibitors for USP7 and USP10［J］. J Mol Biol, 2017, 429(22): 35463560. DOI: 10.1016/j.jmb.2017.05.025. ［8］ Liu J, Kruswick A, Dang H, et al. Ubiquitinspecific protease 21 stabilizes BRCA2 to control DNA repair and tumor growth［J］. Nat Commun, 2017, 8(1): 137149. DOI: 10.1038/s41467017002062. ［9］ PerezOliva AB, Lachaud C, Szyniarowski P, et al. USP45 deubiquitylase controls ERCC1XPF endonucleasemediated DNA damage responses［J］. EMBO J, 2015, 34(3): 326343. DOI: 10.15252/embj.201489184. ［10］ Li Y, Huang W, Xu Y, et al. CYLD deubiquitinase negatively regulates high glucoseinduced NFkappaB inflammatory signaling in mesangial cells［J］. Biomed Res Int, 2017, 2017: 3982906. DOI: 10.1155/2017/3982906. ［11］ Liu C, Wang L, Chen W, et al. USP35 activated by miR let7a inhibits cell proliferation and NFκB activation through stabilization of ABIN2［J］. Oncotarget, 2015, 6(29): 2789127906. DOI: 10.18632/oncotarget.4451. ［12］ Poalas K, Hatchi EM, Cordeiro N, et al. Negative regulation of NFκB signaling in T lymphocytes by the ubiquitinspecific protease USP34［J］. Cell Commun Signal, 2013, 11(1): 25. DOI: 10.1186/1478811X1125. ［13］ Li G, Wang Z, Chong T, et al. Curcumin enhances the radiosensitivity of renal cancer cells by suppressing NFκB signaling pathway［J］. Biomed Pharmacother, 2017, 94: 974981. DOI: 10.1016/j.biopha.2017.07.148. ［14］ Ren K, Li Z, Li Y, et al. Sulforaphene enhances radiosensitivity of hepatocellular carcinoma through suppression of the NFκB pathway［J］. J Biochem Mol Toxicol, 2017, 31(8): e21917. DOI: 10.1002/jbt.21917. ［15］ Villeneuve NF, Tian W, Wu T, et al. USP15 negatively regulates Nrf2 through deubiquitination of Keap1［J］. Mol Cell, 2013, 51(1): 6879. DOI: 10.1016/j.molcel.2013.04.022. ［16］ Boustani MR, Khoshnood RJ, Nikpasand F, et al. Overexpression of ubiquitinspecific protease 2a (USP2a) and nuclear factor erythroid 2related factor 2 (Nrf2) in human gliomas［J］. J Neurol Sci, 2016, 363: 249252. DOI: 10.1016/j.jns.2016.03.003. ［17］ Hou K, Zhu Z, Wang Y, et al. Overexpression and biological function of ubiquitinspecific protease 42 in gastric cancer［J］. PLoS One, 2016, 11(3): e0152997. DOI: 10.1371/journal.pone.0152997. ［18］ Hu W, Wei H, Li K, et al. Downregulation of USP32 inhibits cell proliferation, migration and invasion in human small cell lung cancer［J］. Cell Prolif, 2017, 50(4): e12343. DOI: 10.1111/cpr.12343. ［19］ Kim J, D′annibale S, Magliozzi R, et al. USP17and SCFβTrCPregulated degradation of DEC1 controls the DNA damage response［J］. Mol Cell Biol, 2014, 34(22): 41774185. DOI: 10.1128/MCB.0053014. ［20］ McKeown MR, Bradner JE. Therapeutic strategies to inhibit MYC［J］. Cold Spring Harb Perspect Med, 2014, 4(10). pii: a014266. DOI: 10.1101/cshperspect.a014266. ［21］ Diefenbacher ME, Popov N, Blake SM, et al. The deubiquitinase USP28 controls intestinal homeostasis and promotes colorectal cancer［J］. J Clin Invest, 2014, 124(8): 34073418. DOI: 10.1172/JCI73733. ［22］ Pan J, Deng Q, Jiang C, et al. USP37 directly deubiquitinates and stabilizes cMyc in lung cancer［J］. Oncogene, 2015, 34(30): 39573967. DOI: 10.1038/onc.2014.327. ［23］ Sun XX, He X, Yin L, et al. The nucleolar ubiquitinspecific protease USP36 deubiquitinates and stabilizes cMyc［J］. Proc Natl Acad Sci U S A, 2015, 112(12): 37343739. DOI: 10.1073/pnas.1411713112.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.